Liraglutide paved the way for GLP-1 therapies in obesity treatment, but most patients and clinicians now prefer semaglutide or tirzepatide because of stronger results and easier dosing
Because starting doses are intentionally low, dramatic changes are not usually expected during the first several weeks
Given the lag in prescribing uptake and availability of claims data that affect all retrospective claims analyses, the mean followup period was approximately 8 months for the ITT analysis and 4 months for the perprotocol analysis
Consumer feedback surfaces primarily through Reddit GLP-1 communities, BBB complaint filings, and multi-condition telehealth review platforms
Semaglutide, sold under the brand names Ozempic, Wegovy and Rybelsus, is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management